Connecticut and 19 other states filed a lawsuit against Mylan, Teva Pharmaceuticals and four other generic drug makers saying they entered into illegal conspiracies that raised prices on two common generic drugs, the New York state attorney general’s office said in a statement.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.
Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.
Intarcia Therapeutics Inc. submitted a marketing application for its matchstick-size implantable drug-delivery pump for diabetes to the U.S. FDA.
Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk’s bid to make an oral form of insulin.
A review about two promising applications of digital data to improve patient marketing, plus a third “low-hanging fruit” tactic most brands should explore.
Two prominent U.S. lawmakers called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co., Merck & Co. Inc. and Novo Nordisk A/S colluded to set prices for insulin and other diabetes drugs.
Do sugar-sweetened beverages like soda and fruit drinks cause obesity and diabetes? The answer may depend on who funds the research asking the question.
Verily, Google’s life sciences division, aims to eliminate the threat of the mosquito-borne Zika virus by figuring out how to prevent the pesky pests from reproducing.